Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy

Trial Profile

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2018

At a glance

  • Drugs Avacopan (Primary)
  • Indications Membranoproliferative glomerulonephritis
  • Focus Therapeutic Use
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 08 Nov 2018 According to a ChemoCentryx media release, enrolment in the study is now 61% complete for the initial cohort of 44 patients; 35% complete for the expanded study targeting a combined 88 patients.
    • 06 Aug 2018 The trial has been suspended in Germany.
    • 05 Jun 2018 Planned number of patients changed from 44 to 88.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top